OliPass

OliPass EBITDA per Share

The EBITDA per Share of OliPass (244460.KQ) as of Nov 17, 2026 is -2,058.75 KRW. In the previous year, EBITDA per Share was -2,763.37 KRW — a change of -25.50% (higher).

EBITDA per Share

-2,058.75KRW

YoY

-25.50%

Last updated:

EBITDA per Share of OliPass is 2024 -2,058.75 KRW. EBITDA per Share of OliPass was 2023 -2,763.37 KRW. It decreases by -25.50% higher compared to the previous year.

The OliPass EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-2,662.16 KRW
Jan 1, 2018
-3,628.13 KRW
Jan 1, 2019
-4,327.02 KRW
Jan 1, 2020
-4,798.79 KRW
Jan 1, 2021
-4,970.39 KRW
Jan 1, 2022
-4,859.99 KRW
Jan 1, 2023
-2,763.37 KRW
Jan 1, 2024
-2,058.75 KRW
The OliPass EBITDA per Share history
YEAREBITDA per ShareYoY
-2,058.75KRW-25.50%
-2,763.37KRW-43.14%
-4,859.99KRW-2.22%
-4,970.39KRW+3.58%
-4,798.79KRW+10.90%
-4,327.02KRW+19.26%
-3,628.13KRW+36.29%
-2,662.16KRW+10.80%
-2,402.56KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OliPass Stock analysis

What does OliPass do? OliPass Corp develops and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, and cancer immunotherapy medicine. The company also researches, develops, and sells functional cosmetics using artificial gene platform technology. Its primary customers are healthcare providers and pharmaceutical companies seeking innovative treatments and cosmetic solutions. OliPass Corp generates revenue through the sale of these medical products and functional cosmetics, focusing on biotechnology-driven healthcare and beauty markets. The company's product portfolio includes nonopioid analgesics for pain management, hyperlipidemia medicines for cholesterol control, ocular angiogenesis inhibitors for eye conditions, duchenne dystrophy treatments, and cancer immunotherapy medicines. Functional cosmetics developed via artificial gene platform technology target consumers interested in advanced skincare. OliPass Corp's revenue streams are derived from direct sales to healthcare institutions and pharmaceutical distributors, with a strong emphasis on biotech innovation in both medicine and cosmetics. OliPass Corp's business model centers on developing proprietary biological products through research and development. The firm sells its medicines and functional cosmetics to healthcare providers and pharmaceutical companies, leveraging its artificial gene platform technology for product differentiation. Revenue is generated through the commercialization of its medical and cosmetic product lines, which cater to specific health and beauty segments requiring advanced biotechnological solutions. OliPass is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OliPass stock

EBITDA per Share of OliPass is -2,058.75 KRW in 2024.

EBITDA per Share of OliPass changed from -2,763.37 KRW to -2,058.75 KRW, representing a -25.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share OliPass since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — OliPass

All Key Metrics — OliPass